- Oragenics, Inc. **regained full compliance** with NYSE American's continued listing standards, effective **October 20, 2025**, by resolving its stockholder equity deficiency.  **[1174940_4da53edba12a4d81804d25b157177378_0]** 
- This was achieved through a **$16.5 million public offering of Series H Convertible Preferred Stock** that closed on **July 2, 2025**.  **[1174940_4da53edba12a4d81804d25b157177378_0]** 
- The capital raise provides funding to advance its lead candidate, **ONP-002**, for concussion and mild traumatic brain injury, through Phase II clinical trials in Australia and planned U.S. Phase IIb trials.  **[1174940_4da53edba12a4d81804d25b157177378_0]** **[1174940_4da53edba12a4d81804d25b157177378_1]**

Oragenics Regains NYSE American Compliance

- Oragenics, Inc. **regained full compliance** with NYSE American's continued listing standards, effective **October 20, 2025**, by meeting the **$6 million** stockholders' equity requirement.  **[1174940_0001493152-25-018725_ex99-1.htm:0]** **[1174940_0001493152-25-018725_form8-k.htm:2]** 
- This compliance was achieved through a **$16.5 million public offering of Series H Convertible Preferred Stock** that closed on **July 2, 2025**, which restored equity to compliant levels.  **[1174940_0001493152-25-018725_ex99-1.htm:0]** **[1174940_0001493152-25-018725_form8-k.htm:2]** 
- On **October 16, 2025**, the company settled claims with Ladenburg Thalmann & Co., Inc. by paying **$700,000**, resolving a dispute where Ladenburg had claimed **$2.5 million** was due.  **[1174940_0001493152-25-018725_form8-k.htm:1]** 
- With capital secured and compliance restored, Oragenics will now focus on advancing **ONP-002**, its lead candidate for concussion and mild traumatic brain injury, into Phase IIa clinical trials in Australia and planning for U.S. Phase IIb trials.  **[1174940_0001493152-25-018725_ex99-1.htm:0]**

Oragenics Regains NYSE American Compliance and Settles Claims

- **Oragenics** has formed a strategic collaboration with **Receptor.AI** to utilize artificial intelligence for accelerating the development of pharmaceutical candidates targeting brain health conditions, aiming to expand its drug pipeline beyond ONP-002.  **[1174940_25b54e22467b41fb81ca68f5b0ff0a01]** 
- Its primary candidate, **ONP-002**, a fully synthetic neurosteroid, is currently in **Phase IIa clinical trials** in Australia, with plans to commence Phase IIb trials in the US.  **[1174940_25b54e22467b41fb81ca68f5b0ff0a01]** 
- Following the announcement of the partnership, Oragenics' shares rose by **2.30%** in premarket trading, reaching **$1.33**.  **[1174940_25b54e22467b41fb81ca68f5b0ff0a01]** 
- The company currently has **no revenue or sales**, reflecting its focus on research and development, and faces significant financial challenges.  **[1174940_25b54e22467b41fb81ca68f5b0ff0a01]**

ORAGENICS (OGEN)